Docon Technologies Sells 9.9% Stake in Thyrocare for Rs 986 Crore
Docon Technologies divests 9.9% stake in Thyrocare, raising Rs 986 crore through NSE and BSE deals.
In a significant financial maneuver, Docon Technologies, a prominent promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostics company, generating Rs 986 crore. This transaction was executed through a series of bulk and block deals on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
Details of the Transaction
The sale involved a total of 1,57,69,696 equity shares. More than 1.31 crore shares were exchanged through block deals, while 10 lakh shares were traded via bulk deals on the NSE. Additionally, 16.01 lakh shares were sold through a bulk deal on the BSE. The shares were priced between Rs 624 and Rs 631.71 each, culminating in a transaction valued at Rs 985.86 crore.
Impact on Docon's Holdings
Following this sale, Docon's ownership in Thyrocare Technologies has decreased from 60.92% to 51.02%. The stake sale attracted interest from a range of institutional investors, including mutual funds and insurance companies. Notable buyers included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Prominent insurance firms like Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance also participated, alongside global entities such as Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.
Market Reaction and Historical Context
In the wake of this transaction, Thyrocare Technologies' shares experienced a modest rise. On Friday, shares appreciated nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE. This development follows a similar move by Docon last year when it sold a 10% stake in Thyrocare for Rs 667 crore in October. The consistent reduction in holdings reflects a broader strategy by Docon Technologies, possibly aimed at diversifying its portfolio or capitalizing on market conditions.
While the specific details of other investors involved in the bulk deals remain undisclosed, the participation of high-profile investment firms underscores the market's confidence in Thyrocare Technologies' potential and stability. The transaction highlights the ongoing interest in the healthcare diagnostics sector, a field that continues to draw significant investment due to its critical role in public health.